144 related articles for article (PubMed ID: 32323895)
61. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Jones P; Wilcoxen K; Rowley M; Toniatti C
J Med Chem; 2015 Apr; 58(8):3302-14. PubMed ID: 25761096
[TBL] [Abstract][Full Text] [Related]
62. Cell lines of the same anatomic site and histologic type show large variability in intrinsic radiosensitivity and relative biological effectiveness to protons and carbon ions.
Flint DB; Bright SJ; McFadden CH; Konishi T; Ohsawa D; Turner B; Lin SH; Grosshans DR; Chiu HS; Sumazin P; Shaitelman SF; Sawakuchi GO
Med Phys; 2021 Jun; 48(6):3243-3261. PubMed ID: 33837540
[TBL] [Abstract][Full Text] [Related]
63. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.
Hastak K; Bhutra S; Parry R; Ford JM
Oncotarget; 2017 Apr; 8(16):26344-26355. PubMed ID: 28412751
[TBL] [Abstract][Full Text] [Related]
64. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
65. The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.
Yonemori K; Shimizu T; Kondo S; Iwasa S; Koyama T; Kitano S; Sato J; Shimomura A; Shibaki R; Suri A; Kase Y; Sumino S; Tamura K; Yamamoto N
Jpn J Clin Oncol; 2021 Apr; 51(5):693-699. PubMed ID: 33621324
[TBL] [Abstract][Full Text] [Related]
66. Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
Laban S; Steinmeister L; Gleißner L; Grob TJ; Grénman R; Petersen C; Gal A; Knecht R; Dikomey E; Kriegs M
Radiother Oncol; 2013 Nov; 109(2):286-92. PubMed ID: 23953412
[TBL] [Abstract][Full Text] [Related]
67. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
Macha MA; Rachagani S; Qazi AK; Jahan R; Gupta S; Patel A; Seshacharyulu P; Lin C; Li S; Wang S; Verma V; Kishida S; Kishida M; Nakamura N; Kibe T; Lydiatt WM; Smith RB; Ganti AK; Jones DT; Batra SK; Jain M
Oncotarget; 2017 Mar; 8(13):20961-20973. PubMed ID: 28423495
[TBL] [Abstract][Full Text] [Related]
68. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
69. Niraparib: First Global Approval.
Scott LJ
Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
[TBL] [Abstract][Full Text] [Related]
70. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons.
Ramaekers BL; Pijls-Johannesma M; Joore MA; van den Ende P; Langendijk JA; Lambin P; Kessels AG; Grutters JP
Cancer Treat Rev; 2011 May; 37(3):185-201. PubMed ID: 20817407
[TBL] [Abstract][Full Text] [Related]
71. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
Laird JH; Lok BH; Ma J; Bell A; de Stanchina E; Poirier JT; Rudin CM
Clin Cancer Res; 2018 Oct; 24(20):5143-5152. PubMed ID: 29945991
[No Abstract] [Full Text] [Related]
72. Radiosensitivity of Patient-Derived Glioma Stem Cell 3-Dimensional Cultures to Photon, Proton, and Carbon Irradiation.
Chiblak S; Tang Z; Campos B; Gal Z; Unterberg A; Debus J; Herold-Mende C; Abdollahi A
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):112-119. PubMed ID: 26254681
[TBL] [Abstract][Full Text] [Related]
73. Niraparib for the treatment of ovarian cancer.
Kanjanapan Y; Lheureux S; Oza AM
Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
[TBL] [Abstract][Full Text] [Related]
74. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
[TBL] [Abstract][Full Text] [Related]
75. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract][Full Text] [Related]
76. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
77. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
[TBL] [Abstract][Full Text] [Related]
78. A model for the relative biological effectiveness of protons: the tissue specific parameter α/β of photons is a predictor for the sensitivity to LET changes.
Wedenberg M; Lind BK; Hårdemark B
Acta Oncol; 2013 Apr; 52(3):580-8. PubMed ID: 22909391
[TBL] [Abstract][Full Text] [Related]
79. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
[TBL] [Abstract][Full Text] [Related]
80. Spot Scanning and Passive Scattering Proton Therapy: Relative Biological Effectiveness and Oxygen Enhancement Ratio in Cultured Cells.
Iwata H; Ogino H; Hashimoto S; Yamada M; Shibata H; Yasui K; Toshito T; Omachi C; Tatekawa K; Manabe Y; Mizoe JE; Shibamoto Y
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):95-102. PubMed ID: 27084632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
